scholarly journals A real-world, non-interventional Indian study on clinical assessment of intense moisturizing formulation in dry skin disorders

2021 ◽  
Vol 7 (6) ◽  
pp. 848
Author(s):  
Dhiraj S. Dhoot ◽  
Namrata Mahadkar ◽  
Hanmant Barkate
Keyword(s):  
Atopic Dermatitis ◽  
Global Assessment ◽  
Severity Index ◽  
Physician Global Assessment ◽  
Skin Area ◽  
Skin Disorders ◽  
Dry Skin ◽  
Product Categories ◽  
Retrospective Data Analysis ◽  
Good Improvement

<p><strong>Introduction: </strong>Moisturizers account for the largest and important skin care product categories and are the backbone in the management of dry skin conditions associated with atopic dermatitis (AD), psoriasis and ichthyosis. </p><p><strong>Methods: </strong>A multicentre, retrospective data analysis was done at 145 dermatology clinics across India in patients who were prescribed MaxRich®. Patients with history of xerosis with an identifiable causes like atopic dermatitis, psoriasis and ichthyosis were included in study. Effectiveness data in terms of improvement in Dry Skin Area and Severity Index (DASI) Score compared to baseline and physician global assessment at the end of treatment for improvement in xerosis were captured.</p><p><strong>Results: </strong>There was significant reduction in mean DASI score as compared to baseline at week 2 &amp; 4 (p&lt;0.01). As compared to baseline, a significant decrease in DASI score was observed by 47.7% and 82.4% at the end of week 2 and 4 respectively. As per physician global assessment, 458 patients (83.4%) noticed very good improvement in xerosis at the end of 4 weeks whereas 82 patients (14.9%) recorded moderate improvement. Similar results were also obtained for patient global assessment where 478 patients (87%) recorded very good improvement; 67 patients (12.2%) and 6 patients (1.1%) recorded moderate and mild improvement respectively. There were no adverse events reported with MaxRich®.</p><p><strong>Conclusion: </strong>MaxRich®, an intense moisturizer was effective in improvement of DASI score associated with atopic dermatitis, psoriasis and ichthyosis and can be considered as an adjunct therapy in the management of these skin disorders for better results.</p>

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis

2018 ◽  
Vol 22 (1_suppl) ◽  
pp. 10S-16S ◽  
Author(s):  
Melinda J. Gooderham ◽  
Robert Bissonnette ◽  
Parbeer Grewal ◽  
Perla Lansang ◽  
Kim A. Papp ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Disease Severity ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Life Quality ◽  
Severity Index ◽  
Adult Patients ◽  
Physician Global Assessment ◽  
Atopic Dermatitis Severity ◽  
Patient Reported

Clinicians rely on clinical measures to define the severity of atopic dermatitis and assess outcomes of therapy. These measures can be objective (ie, physician assessments of disease severity) or subjective (ie, patient-reported symptoms and quality of life outcomes). In this review, the most commonly used tools for assessing atopic dermatitis severity in adult patients are presented and compared. These include Eczema Area and Severity Index (EASI); SCORing Atopic Dermatitis (SCORAD); Physician Global Assessment (PGA); body surface area (BSA); Atopic Dermatitis Severity Index (ADSI); Six Area, Six Sign Atopic Dermatitis (SASSAD); Patient Oriented Eczema Measure (POEM); Dermatology Life Quality Index (DLQI); and pruritus Numerical Rating Scale (NRS). Available severity strata for the tools are summarized, although the use of severity strata in clinical practice is not recommended. Since both objective and subjective assessments of disease severity are important to assess, consideration of clinical characteristics such as disease recurrence or persistence, as well as location of the affected areas, should be considered in the overall judgement of disease severity and consideration of therapy choice.

Management of Pruritus

2010 ◽  
Vol 3 (7) ◽  
pp. 384-387 ◽  
Author(s):  
Ferhat Uddin
Keyword(s):  
Atopic Dermatitis ◽  
Effective Treatment ◽  
Disease Process ◽  
Underlying Disease ◽  
Skin Disorders ◽  
Dry Skin ◽  
Lichen Simplex Chronicus ◽  
Complex Process ◽  
Underlying Disease Process

Pruritus, or itch, is a common sensation that causes a person to want to scratch. It is a complex process that commonly occurs with skin disorders such as xerotic eczema, atopic dermatitis and urticaria. It may also be related to an underlying disease process such as cholestasis or hyperthyroidism or simply be caused by dry skin, especially in the cold. Effective treatment of pruritus can prevent scratch-induced complications such as lichen simplex chronicus and impetigo. Therapy is often aimed at eliminating the underlying cause first, followed by the management of the itchy sensation.

scholarly journals Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT

2013 ◽  
Vol 40 (5) ◽  
pp. 647-652 ◽  
Author(s):  
Philip J. Mease ◽  
Michele Heckaman ◽  
Sonja Kary ◽  
Hartmut Kupper
Keyword(s):  
Psoriatic Arthritis ◽  
Disease Activity ◽  
Global Assessment ◽  
Health Assessment ◽  
Severity Index ◽  
Tender Joint Count ◽  
Physician Global Assessment ◽  
Minimal Disease Activity ◽  
Tender Joint ◽  
Minimal Disease

Objective.This posthoc analysis evaluated the percentage of patients with psoriatic arthritis (PsA) who achieved minimal disease activity (MDA) and compared the results with a modified MDA substituting the physician global assessment (PGA) for the Psoriasis Activity and Severity Index (PASI) using data from the ADalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT; NCT00646386).Methods.Patients with active PsA were randomized to receive adalimumab 40 mg or placebo every other week for 24 weeks. MDA was defined as achieving ≥ 5 of the following criteria: tender joint count ≤ 1; swollen joint count ≤ 1; PASI ≤ 1 or body surface area ≤ 3%; patient pain score ≤ 15 [1–100 mm visual analog scale (VAS)]; patient global assessment (PGA) of disease activity ≤ 20 (1–100 mm VAS); Health Assessment Questionnaire ≤ 0.5; and tender entheseal points ≤ 1 (only heels assessed). For modification of the MDA, PASI ≤ 1 was substituted with PGA “Clear” as MDAPGA1 and PGA “Clear” or “Almost clear” as MDAPGA2.Results.Sixty-seven patients were treated with adalimumab and 69 with placebo. At Week 24, MDA, MDAPGA1, and MDAPGA2 were achieved by 39%, 37%, and 39%, respectively, of patients treated with adalimumab versus 7%, 5%, and 8% of patients on placebo (p < 0.001). Kappa coefficients indicated good agreement between PASI and PGA at Week 24.Conclusion.ADEPT results indicated that significantly more patients treated with adalimumab achieved MDA by Week 24 compared with placebo. Modification of the MDA by replacing PASI ≤ 1 with PGA assessments did not alter the results, which may improve feasibility of practical use of the index.

scholarly journals Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis

2021 ◽  
Author(s):  
Jacob P. Thyssen ◽  
Chuanbo Zang ◽  
Maureen P. Neary ◽  
Andrew G. Bushmakin ◽  
Joseph C. Cappelleri ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Global Assessment ◽  
Severity Index
Sign in / Sign up

Export Citation Format

Share Document